GPR65 Inhibition as a Strategy to Overcome Chronic Acidosis-Mediated Immune Suppression in Solid Tumours & Identification of PTT-4256 as a Clinical Development Candidate
Time: 3:30 pm
day: Conference Day Two
Details:
- Genetic validation of GPR65 as an immuno-oncology target
- PoC studies with tool GR65 inhibitor molecules demonstrating efficacy in pre-clinical tumour models
- Identification of PTT-4256 as a first in class inhibitor of GPR65 and path to the clinic
